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Abstract
Background: A positive association between IgE sensitisation and exhaled NO levels has been
found in several studies, but there are no reports on the compartment of the lung that is
responsible for the increase in exhaled NO levels seen in IgE-sensitised subjects.
Methods:  The present study comprised 288 adult subjects from the European Community
Respiratory Health Survey II who were investigated in terms of lung function, IgE sensitisation (sum
of specific IgE), smoking history and presence of rhinitis and asthma. Mean airway tissue
concentration of NO (CawNO), airway transfer factor for NO (DawNO), mean alveolar
concentration of NO (CalvNO) and fractional exhaled concentration of NO at a flow rate of 50 mL
s-1 (FENO 0.05) were determined using the extended NO analysis.
Results: IgE-sensitised subjects had higher levels (geometric mean) of FENO 0.05 (24.9 vs. 17.3 ppb)
(p < 0.001), DawNO (10.5 vs. 8 mL s-1) (p = 0.02) and CawNO (124 vs. 107 ppb) (p < 0.001) and
positive correlations were found between the sum of specific IgE and FENO 0.05, CawNO and DawNO
levels (p < 0.001 for all correlations). Sensitisation to cat allergen was the major determinant of
exhaled NO when adjusting for type of sensitisation. Rhinitis and asthma were not associated with
the increase in exhaled NO variables after adjusting for the degree of IgE sensitisation.
Conclusion: The presence of IgE sensitisation and the degree of allergic sensitisation were related
to the increase in airway NO transfer factor and the increase in NO concentration in the airway
wall. Sensitisation to cat allergen was related to the highest increases in exhaled NO parameters.
Our data suggest that exhaled NO is more a specific marker of allergic inflammation than a marker
of asthma or rhinitis.
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Background
An increase in exhaled nitric oxide (NO) levels due to IgE
sensitisation was first observed in laboratory animal
allergy [1] and asymptomatic atopic subjects[2]. A posi-
tive association between exhaled NO levels and the degree
of IgE sensitisation has been found both in children [3-6]
and in the adult population [7]. In these investigations,
the degree of IgE sensitisation has been measured as the
number of positive allergens in skin prick testing[3,6,7] or
the sum of the weal diameters for the investigated aller-
gens (skin prick test index) in children[4,5]. Recently, cal-
culating the sum of specific IgE levels against the allergens
of interest has been proposed as an alternative method for
measuring the degree of IgE sensitisation[8,9].
The mechanism behind the increased levels of exhaled
NO in IgE-sensitised subjects is not fully understood.
Atopic, non-asthmatic subjects often have a subclinical
airway inflammation[10]. This eosinophilic inflamma-
tion causes lung tissue damage followed by the release of
cytokines and the stimulation of inducible nitric oxide
synthase (iNOS). Exposure to allergens might also stimu-
late bronchial epithelium iNOS [11] and increase exhaled
NO levels. It has also been proposed that there is a com-
mon gene that regulates iNOS and atopic activity [12].
The increase in epithelial iNOS activity probably explains
the increase in NO levels in IgE-sensitised subjects, since
epithelial iNOS activity has been shown to be the main
determinant of FENO in humans[13].
It is possible to obtain a greater insight into the two NO-
producing compartments, the airways and alveoli, by
modelling NO exchange dynamics. These models are
characterised by two or three NO flow-independent
parameters, depending on the model [14]. There are no
studies which directly analyse the effects of IgE sensitisa-
tion on NO flow-independent parameters. Subjects with
allergic asthma [15-17] have been found to have increased
NO concentrations in the airway wall and a higher NO
airway transfer factor than healthy controls, while subjects
with allergic rhinitis[17] have been found to have a higher
NO airway transfer factor. These previous studies did not
include subjects with non-allergic asthma or rhinitis and
it is therefore not possible to understand the impact of IgE
sensitisation alone on NO flow-independent parameters
from the studies published so far.
The aim of the present investigation was to study where
the NO responsible for the increase in the levels of
exhaled NO seen in IgE-sensitised subjects comes from.
Methods
Population
The European Community Respiratory Health Survey
(ECRHS) is an international multi-centre study of asthma
and allergy. The first part, ECRHS I, was conducted in
1990–1994 and the follow-up study, ECRHS II, in 1999–
2001. The design of ECRHS I and ECRHS II has been pub-
lished in detail[18,19]. Each participant was sent a brief
questionnaire (Stage 1) and, from those who responded,
a random sample was invited to undergo a more detailed
clinical examination (Stage 2). A "symptomatic sample"
consisting of additional subjects who reported symptoms
of waking with shortness of breath, asthma attacks or
using asthma medication in Stage 1 was also studied. In
ECRHS II, subjects who had participated in Stage 2 of
ECRHS I were invited to participate in a follow-up study.
Subjects answered a standardised questionnaire adminis-
tered by trained interviewers and underwent lung func-
tion tests and blood tests.
Of the 823 subjects who participated in Stage 2 of the
ECRHS in Uppsala, 679 were re-investigated nine years
later (1999–2000) in the ECRHS II[19]. Of these, 489
were seen at the hospital for a clinical examination, lung
function tests and blood tests, while the remaining sub-
jects only participated in a telephone survey, usually
because they had moved outside the study area between
the two surveys. Of the subjects who attended the clinical
examination, 288 (59%) were also willing to perform
exhaled NO measurements at multiple flow rates.
Questionnaires
The ECRHS II main questionnaire http://
www.ecrhs.org[19] was used to obtain information about
allergic symptoms, exposure to investigated allergens and
smoking history.
Measurements of exhaled NO
The NO measurements were performed according to
American Thoracic Society (ATS) recommendations, apart
from the use of three additional flows (5, 100 and 500 mL
s-1) and no vital capacity manoeuvre, as a deep breath
with slow inhalation was found to be sufficient[20].
The system used for NO measurements was a computer-
based, single-breath NO system from Nitrograf AB, Häs-
selby, Sweden, which used a chemiluminescence analyser
(Sievers NOA 280, Sievers, Boulder, CO, USA). The sys-
tem was calibrated using a mixture of 460 ppb NO in
nitrogen (AGA AB, Lidingö, Sweden) and the zero was set
by feeding synthetic air (AGA AB) into a 2 L canister filled
with Purafil II chemisorbant with purakol (Lindair AB,
Ljusne, Sweden). The flow sensor was calibrated in the
range of 0–0.6 L sec-1 (Dry Cal DC-2 flow calibrator, BIOS
International, Pompton Plains, NJ, USA). Checks of the
calibration and flow rate of the sampling system were
made on a daily basis and the zero was controlled before
each measurement. The expiratory pressure for all subjects
was between 5 and 20 cm H2O in order to exclude a NORespiratory Research 2006, 7:92 http://respiratory-research.com/content/7/1/92
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contribution from the nasal cavity. A mean value of three
breaths (or two if the NO concentrations were identical
from the two breaths) was used for statistical analysis.
Application of the extended NO analysis
The extended NO analysis has previously been described
and validated[17]. Using the values of fractional exhaled
nitric oxide (FENO) collected at three different flow rates
(5, 100 and 500 mL s-1) and an iteration algorithm, it cal-
culates the three flow-independent NO parameters con-
fined to the two compartments: conducting airways,
which are characterised by the mean airway tissue concen-
tration of NO (CawNO) and NO airway transfer factor
(DawNO), and alveoli, characterised by a mean alveolar
tissue concentration of NO (CalvNO). The fractional
exhaled nitric oxide value at a flow rate of 50 mL s-1 (FENO
0.05) was used as a measure of the overall exhaled NO con-
centration. We chose to use the FENO 0.05 value in order to
have a reference value for the other studies and to comply
with ATS recommendations [21].
Lung function
Forced expiratory volume in one second (FEV1) was meas-
ured using a dry rolling seal spirometer system (Sensor
Medics 2130, Sensor Medics, Anaheim, California, USA).
Up to five technically acceptable blows were determined.
The ATS recommendations were followed[22]. The pre-
dicted values for forced expiratory volume in one second
(FEV1) were calculated on the basis of the European Coal
and Steel Union reference values[23].
IgE sensitisation
Blood samples were collected for the measurement of
total and specific serum IgE using the Pharmacia CAP Sys-
tem (Pharmacia Diagnostics, Uppsala, Sweden). Specific
IgE was measured against Dermatophagoides pteronyssinus,
cat, timothy grass and Cladosporium herbarum. The detec-
tion of specific IgE of ≥ 0.35 kU/l was used as a definition
of sensitisation to a specific allergen. IgE sensitisation was
defined as sensitisation to at least one of the investigated
allergens.
The degree of sensitisation was defined in two ways: either
based on the number of allergens to which one person
was sensitised or using a continuous variable – the sum of
specific IgE – that has been defined as the sum of the spe-
cific IgE titres for the investigated allergens.
A titre below the detection level (<0.35 kU/L) was arbitrar-
ily given the value 0.17 kU/L.
Diagnosis of asthma and rhinitis
A positive diagnosis of rhinitis was made in the individu-
als who answered positively to the question "Do you have
any nasal allergies, including hay fever?".
A person was recorded as having asthma if he/she had ever
been diagnosed with asthma and had an asthma attack or
one of the following symptoms during the last 12
months: nocturnal chest tightness, attack of shortness of
breath, chest wheezing or whistling[24].
Smoking history
Information on smoking history was retrieved from the
main questionnaire, in ECRHS II. Those who answered
"yes" to the lead question ("Have you ever smoked for as
long as a year?") were classified as ex-smokers and current
smokers based on a negative/positive answer to the ques-
tion regarding current consumption ("Do you now
smoke, as of one month ago?").
Statistical methods
Statistical analyses were performed using STATA 8.0 soft-
ware (Stata Corp., 2001, Texas, USA). NO values, specific
IgE titres, the sum of specific IgE titres and total IgE titres
were log transformed before analysis. Chi-squared test
and unpaired t-test were used when comparing subjects
who performed NO measurements and the rest of the sub-
jects in ECRHS II. Unpaired t-test was used when compar-
ing exhaled NO and NO flow-independent parameters
between sensitised and non-sensitised subjects. Linear
regression was used in the bivariate analyses to analyse the
correlation between the degree of IgE sensitisation and
exhaled NO variables. Multiple linear regression was used
when analysing the effect of different explanatory varia-
bles on exhaled NO and the NO flow-independent
parameters. These models always included age, gender,
height, FEV1 and smoking history. A p-value of < 0.05 was
considered statistically significant.
Ethics
All the subjects gave their permission for the utilisation of
personal data for the purpose of this study. The study was
approved by the Ethics Committee at the Medical Faculty
at Uppsala University.
Results
The subjects who underwent exhaled NO measurements
(Table 1) did not differ from the other ECRHS II partici-
pants in terms of IgE sensitisation and smoking history.
However, there were differences between the investigated
group and the rest of the subjects in terms of age (43 vs.
41 years, p < 0.0001) and gender distribution (44.8%
women vs. 53.8% women, p = 0.01).
IgE sensitisation
IgE sensitisation was associated with higher levels of FENO
0.05, CawNO and DawNO (Table 2). The associations with
FENO 0.05 and DawNO remained significant after adjusting
for potential confounders (gender, height, age, smoking
history and FEV1) (Table 2).Respiratory Research 2006, 7:92 http://respiratory-research.com/content/7/1/92
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Degree of sensitisation
FENO 0.05 and the airway NO flow-independent parameters
increased with the number of allergens to which the sub-
ject was sensitised (p for trend <0.001 for FENO 0.05, p =
0.02 for CawNO and p < 0.001 for DawNO), while there was
no significant correlation between the number of aller-
gens and CalvNO (p = 0.75) (Figure 1). These associations
remained statistically significant after adjusting for gen-
der, height, age, smoking history and FEV1.
Significant correlations were found between the sum of
specific IgE titres and FENO 0.05 (r = 0.40, p < 0.0001),
CawNO (r = 0.24, p < 0.0001) and DawNO (r = 0.26, p <
0.0001) respectively (Figure 2). All these relationships
were maintained after adjusting for the possible con-
founders (p < 0.001). No correlation was found with
CalvNO (p = 0.55). Total IgE was also significantly associ-
ated with the exhaled NO variables, but the correlation
was lower than that found for the sum of specific IgE
(FENO 0.05 (r = 0.23, p < 0.001), CawNO (r = 0.15, p = 0.01)
and DawNO (r = 0.13, p = 0.03)).
Sensitisation to specific allergens
Sensitisation to all allergens except mite was associated
with higher FENO 0.05 levels (Figure 3). There was, for
example, an increase of 57% in FENO 0.05 in the cat-aller-
gen-sensitised subjects compared with cat allergen non-
sensitised subjects. Sensitisation to cat allergen was also
associated with higher CawNO and DawNO levels, while
sensitisation to timothy was associated with higher
CawNO levels and sensitisation to mite with higher DawNO
levels (Figure 3).
Significant correlations were found between the IgE titre
against cat allergen and FENO 0.05 (r = 0.39, p < 0.001),
CawNO (r = 0.26, p < 0.001) and DawNO (r = 0.23, p <
0.001) respectively (Table 3). A significant positive corre-
lation between exhaled NO and the IgE titre against timo-
Table 2: Exhaled NO levels (ppb, geometric mean (95% CI)) in non-sensitised and sensitised subjects
Non sensitised (n = 177) Sensitised (n = 111) p-value p-value after adjustments
FENO 0.05 (ppb) 17.3 (16.0–18.7) 24.9 (21.9–28.4) <0.0001 <0.001
CawNO (ppb) 107 (98.5–115) 124 (111–139) 0.02 0.059
DawNO (mL s-1) 8.00 (7.35–8.71) 10.5 (9.52–11.6) 0.0001 0.002
CalvNO (ppb) 1.28 (1.12–1.46) 1.41 (1.22–1.62) 0.35 0.23
Table 1: Characteristics of study population
Age (mean (range)) 43 (29–54)
Gender (M/F) 159 (55%)/129 (45%)
Smoking status* Non-smokers Smokers
237 (83%) 49 (17%)
Atopy status Non-atopic Atopic
177 (61%) 111 (39%)
Allergen Cat Timothy Mite Cladosporium
Sensitised subjects 75 (26%) 65 (23%) 26 (10%) 8 (3%)
Titres of sIgE(kU/L) 1.47 (0.98, 2.20) 1.23 (0.86, 1.76) 1.71 (0.94, 3.12) 1.95 (0.66, 5.74)
Respiratory disease# None Asthma +/- rhinitis Only rhinitis
All subjects 148 (52%) 57 (20%) 80 (28%)
Sensitized subjects 22 (15%) 42 (74%) 46 (58%)
On daily therapy§ 1 (1%) 15 (26%) 1 (1%)
All results expressed as N(%) or geometric mean (95% CI) with the exception of age.
* Smoking status was not recorded for 2 subjects.
# Information on respiratory disease was not available for 3 subjects.
§ with inhaled corticosteroids or oral antileukotrienesRespiratory Research 2006, 7:92 http://respiratory-research.com/content/7/1/92
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thy was also found (FENO 0.05 (r = 0.27, p < 0.001), CawNO
(r = 0.16, p = 0.008) and DawNO (r = 0.18, p = 0.002)),
while the IgE titre against mite correlated positively with
FENO 0.05 (r = 0.16, p = 0.007) and DawNO (r = 0.16, p =
0.005).
The association between the IgE titre against cat and the
exhaled NO variables remained significant after adjusting
for the specific IgE levels against the other allergens, gen-
der, height, age, smoking history and FEV1 (Table 3).
No significant difference in exhaled NO levels was found
between cat-sensitised subjects who did not have a cat (n
= 63) and those that had a cat (n = 12): FENO 0.05 27.5
(23.2–32.6) vs 30.0 (17.1–52.4) ppb (p = 0.70), CawNO
132 (115–153) vs 135 (77.9–234) ppb (p = 0.92) and
DawNO 11.0 (9.7–12.5) vs 11.8 (8.9–15.7) mL s-1 (p =
0.66).
Asthma and rhinitis
Subjects with rhinitis (n = 79) and asthma (n = 42) had
higher FENO 0.05 levels (22.3 and 27.8 vs. 17.4 ppb) (p =
0.01 and p < 0.001 respectively) than subjects without a
respiratory disease (n = 147). Subjects with asthma also
had higher DawNO (10.8 vs. 8.1 mL s-1) (p = 0.009) and a
trend towards increased CawNO (135 vs 107 ppb) (p =
0.057) than subjects without a respiratory disease, while
the subjects with rhinitis displayed a trend towards
increased DawNO (9.6 vs. 8.1 mL s-1) (p = 0.07). No differ-
ences were found regarding CalvNO between the three
investigated groups (1.42 and 1.48 vs. 1.24 ppb) (p >
0.05). Subjects using inhaled corticosteroids or oral anti-
leukotrienes (n = 17) on a daily basis were excluded from
this analysis.
The association between rhinitis and asthma and FENO 0.05
remained significant after adjusting for gender, age,
Exhaled NO and flow-independent airway NO exchange parameters in relation to the degree of sensitisation, assessed by the  number of allergens to which one person was sensitised Figure 1
Exhaled NO and flow-independent airway NO exchange parameters in relation to the degree of sensitisation, 
assessed by the number of allergens to which one person was sensitised. Box-plot explanation: upper horizontal line 
of box, 75th percentile; lower horizontal line of box, 25th percentile; horizontal bar within box, median; upper horizontal bar 
outside box, upper adjacent value; lower horizontal bar outside box, lower adjacent value
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height, smoking history and lung function (FEV1). Both
having rhinitis and having asthma were associated with
increases in DawNO  (Table 4). All these associations
became statistically non-significant after adjusting for the
degree of sensitisation (Table 4). The degree of sensitisa-
tion was related to exhaled NO and airway flow-inde-
pendent NO exchange parameters even after adjustment
for rhinitis and asthma (Table 4).
Discussion
The main finding in the present study was that IgE sensi-
tisation was related to an increase in airway NO transfer
factor and an increase in NO concentration in the airway
wall. These NO variables were also positively related to
the degree of allergic sensitisation. Sensitisation to cat
allergen was the allergen sensitisation related to the high-
est increases in exhaled NO levels. The presence of asthma
or rhinitis was not related to the exhaled NO variables
after adjusting for the degree of sensitisation, suggesting
that exhaled NO is probably more a specific marker of
allergic inflammation than a marker of asthmatic inflam-
mation.
The present study is the first to analyse the relationship
between IgE sensitisation and NO flow-independent
parameters. The increased CawNO in IgE-sensitised sub-
jects probably reflects an increase in NO production due
to the induction of iNOS in the airway epithelial cells, the
main determinant of NO concentration in exhaled breath
according to a recent study[13]. Other possible mecha-
nisms include an increase in S-nitrosoglutathione
(GSNO) reductase activity with an increase in NO release
through the breakdown of S-nitrosothiols [25]. Another
possible explanation is that allergic asthma is associated
with a lower pH in the airway fluid [26], which may
increase NO release through the protonation of nitrite
and the production of nitrous acid. The increased DawNO
observed in IgE-sensitised subjects may be partly related
to the inflammation in the peripheral airways [27] which
potentially increases the NO producing surface[15].
Exhaled NO and flow-independent airway NO exchange parameters in relation to degree of sensitisation, quantified by the  sum of specific IgE titres against investigated allergens Figure 2
Exhaled NO and flow-independent airway NO exchange parameters in relation to degree of sensitisation, quantified by the 
sum of specific IgE titres against investigated allergens.
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Another explanation is an increase in the diffusion of NO
towards the lumen caused by epithelial damage[28,29],
thickened basement membrane[28,29] and subepithelial
fibrosis[30].
The lack of a relationship between allergic sensitisation
and CalvNO suggests that no alveolar inflammation is
caused by the IgE sensitisation per se. Allergic asthma has
been "classically" reported as only having a bronchial
inflammation component[16]. However, some recent
studies report that symptomatic asthmatic patients
[31,32] also have an alveolar component in the inflam-
mation.
In the present study, exhaled NO levels and flow-inde-
pendent airway NO-exchange parameters were related to
the degree of allergic sensitisation. This was found both
when assessing the level of sensitisation by the number of
allergens and when adding the specific IgE titres. Franklin
et al. [3] first reported the association between exhaled
NO levels and the number of positive skin prick tests, an
association that persisted even after adjusting for con-
founders. The association between exhaled NO levels and
the skin prick test index was first reported by Barreto et al.
[4]. Assessing the degree of sensitisation by adding the
specific IgE titres was first proposed by Wickman et al. [8],
who reported that, by using a combination of the number
of positive allergens at test and the sum of specific IgE lev-
els, it was possible to detect 90% of the individuals with
an allergic disease. Syk et al. [9] reported that there was a
relationship between the sum of specific IgE for perennial
allergens (cat, dog, horse, mite and mould) and exhaled
NO levels (r = 0.47). Total IgE may also be used to assess
the degree of sensitisation and, in asthmatic children, Car-
dinale and co-workers[33] found a closer relationship
between exhaled NO levels and total IgE (r = 0.42) than
between the number of positive SPT and exhaled NO (r =
0.31). In the present study, the sum of specific IgE levels
Exhaled NO ratio and flow-independent airway NO exchange parameters ratio between sensitised and non-sensitised subjects  to a specific allergen (ratio of geometric means (95% CI)) Figure 3
Exhaled NO ratio and flow-independent airway NO exchange parameters ratio between sensitised and non-sensitised subjects 
to a specific allergen (ratio of geometric means (95% CI)).
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was more closely related to exhaled NO levels than total
IgE levels. A similar finding was reported in a recent
study[5] in which exhaled NO was more closely related to
prick index (r = 0.37) than to total IgE levels (r = 0.22).
Sensitisation to cat allergen was the type of sensitisation
that was most closely related to exhaled NO. This is in
accordance with other studies showing that perennial
allergens and not seasonal allergens are the main determi-
nants of high exhaled NO levels [4,34,35]. There are, how-
ever, geographical differences regarding both sensitisation
to different allergens[36] and the type of allergen that
appears to play the most important role. In Southern
Europe, mite sensitisation is the main determinant of
increased exhaled NO levels[4], while in Northern Europe
pet allergens (cat and dog) are the allergens that have the
greatest impact on exhaled NO levels[6].
No differences in exhaled NO levels were found between
cat-allergen-sensitised subjects who had or did not have a
cat. This result is in accordance with a study of schoolchil-
dren from the same geographical region[6], while studies
using measured allergen exposure have produced conflict-
ing results[37,38]. The lack of association between pet
ownership and exhaled NO is probably related to the fact
that cat allergen is widespread in Sweden and basically
everybody is exposed to it in low doses [39].
Rhinitis and asthma were no longer independent determi-
nants of exhaled NO after adjusting for the degree of IgE
sensitisation. Our results are in line with recent stud-
ies[7,40] supporting the theory that the increase in FENO
values reported in allergic respiratory diseases are more
due to the atopic status (IgE sensitisation) than to the res-
piratory disease per se. In contrast to this, an independent
effect of both asthma and sensitisation to perennial aller-
gens on FENO was found in a recent Swedish study[41]. In
this study of bleachery workers, no adjustment was, how-
ever, made for the degree of sensitisation. The results of a
recent study [42] using exhaled NO to adjust the inhaled
corticosteroid doses in the treatment of asthma do, how-
ever, support the notion that exhaled NO levels are related
to some extent to the asthmatic inflammation and not
only to the degree of IgE sensitisation.
The main problem when it comes to interpreting our
results is the relatively low participation rate. There were,
however, no significant differences between the partici-
pants and non-participants regarding IgE sensitisation
and smoking and we therefore do not feel that this has
Table 3: Association between IgE titres against specific allergens and exhaled NO levels after adjustments for IgE titres of other 
allergens, gender, height, age, smoking history and FEV1
Cat Timothy Mite Mould
FENO 0.05 0.14 (0.10, 0.19) 0.02 (-0.03, 0.07) 0.06 (-0.03, 0.14) -0.06 (-0.21, 0.09)
CawNO 0.10 (0.05, 0.15) 0.01 (-0.04, 0.05) -0.01 (-0.09, 0.07) -0.04 (-0.18, 0.11)
DawNO 0.06 (0.02, 0.11) 0.01 (-0.03, 0.06) 0.08 (-0.004, 0.16) -0.03 (-0.18, 0.12)
CalvNO 0.02 (-0.05, 0.10) -0.01 (-0.08, 0.06) 0.03 (-0.10, 0.15) -0.03 (-0.26, 0.19)
The effect estimate was log transformed and presented with a 95% confidence interval.
Table 4: Association between exhaled NO and airway flow-independent NO exchange parameters and rhinitis, asthma and the sum of 
specific IgE with and without adjustment for the variables in the table.
Unadjusted* Adjusted **
Rhinitis FENO 0.05 0.13 (0.06, 0.19) 0.05 (-0.02, 0.012)
CawNO 0.06 (-0.003, 0.12) 0.01 (-0.06, 0.08)
DawNO 0.08 (0.01, 0.14) 0.04 (-0.03, 0.11)
Asthma FENO 0.05 0.18 (0.09, 0.26) 0.07 (-0.03, 0.16)
CawNO 0.08 (-0.0004, 0.16) 0.01 (-0.08, 0.10)
DawNO 0.11 (0.03, 0.20) 0.06 (-0.03, 0.16)
Sum of specific IgE FENO 0.05 0.18 (0.13, 0.23) 0.15 (0.08, 0.21)
CawNO 0.10 (0.05, 0.15) 0.09 (0.03, 0.16)
DawNO 0.10 (0.05, 0.15) 0.07 (0.01, 0.13)
The effect estimate was log transformed and presented with a 95% confidence interval.
Subjects using inhaled corticosteroids or oral anti-leukotrienes on a daily basis were excluded from the analysis.
* Adjusted for gender, age, height, FEV1 and smoking history but not adjusted for the variables in the table
** Adjusted both for the variables in the table and gender, age, height, FEV1 and smoking historyRespiratory Research 2006, 7:92 http://respiratory-research.com/content/7/1/92
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affected our results to any marked degree. Another prob-
lem is related to the choice of allergens. Birch, one of the
most common allergens in Sweden, was not included in
the study. Previous studies examining the correlation
between different IgE titres and NO have only found a
weak correlation between IgE titres against birch and
exhaled exhaled NO [6,9]. Monosensitisation to birch
allergen is not so common and an analysis from the
ECRHS I study [43] has confirmed that after excluding
birch sensitisation there was only a modest decrease in the
prevalence of IgE sensitisation. The definition of asthma
in the present study was based on self reported diagnosed
asthma in combination with asthma symptoms within
the last 12 months. De Marco et al. [44] analyzed data
from the three Italian ECRHS I centres and reported that
this definition of asthma underestimated the actual
number of subjects with clinical verified asthma. This
could be one reason for the differences between our study
and a recent study [45] that found that exhaled NO was a
valuable method for diagnosing asthma in subjects with
suggestive symptoms of asthma. It should, however, be
noted that the prevalence of atopy in the cited study was
76% in those that were diagnosed as having asthma and
43% in the non-asthmatic group.
Conclusion
IgE sensitisation is related to an increase in airway NO
transfer factor and an increase in NO concentration in the
airway wall. These NO variables were also positively
related to the degree of allergic sensitisation. Sensitisation
to cat allergen was related to the highest increases in
exhaled NO levels. Our data suggest that exhaled NO is
probably more a specific marker of allergic inflammation
than a marker of asthmatic inflammation.
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